CDNA vs EXAS
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 11, 2026
CDNA
EXAS
Investment Advisor Scores
EXAS
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CDNA | EXAS | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 68.9655 | 243.9024 | CDNA |
| PEG Ratio | -0.12 | -1.07 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 39.3% | 23.1% | CDNA |
| Earnings Growth | 1066.7% | 0.0% | CDNA |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 24.9/100 | 52.3/100 | EXAS |
| Profit Margin | 25.9% | -6.4% | CDNA |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG SELL | HOLD | EXAS |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CDNA
MarkupPrice above SMA50, rising 50-day trend (20.4% over 20 days), RSI 60
EXAS
MarkupPrice above SMA50, rising 50-day trend (0.8% over 20 days), RSI 76
Fundamentals Snapshot
| Metric | CDNA | EXAS |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 51.4 | 55.8 |
| Trailing P/E | 34.1 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.4% | 0.2% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.1% | -0.1% |
| EPS | 2.37 | -1.10 |
| Dividend Yield | — | — |